FDA Reverses Course on Moderna Flu Vaccine, Scrutinizes Telehealth GLP-1s

The Food and Drug Administration (FDA) is navigating a period of significant shifts, recently reversing its stance to review Moderna’s mRNA flu vaccine for adults aged 50, and older. This decision comes as the agency too increases scrutiny of telehealth companies prescribing compounded GLP-1 medications for weight loss.

Moderna’s Flu Vaccine Receives Second Appear

After initially rejecting Moderna’s application, the FDA will now review data for its mRNA influenza vaccine in adults aged 50 to 64. This reversal, announced on February 18, 2026, signals a potential turning point for the company’s efforts to expand its vaccine portfolio beyond COVID-19. The initial rejection raised concerns about the study design, specifically its comparison points, according to some experts.

FDA Warns Telehealth Firms on Compounded GLP-1s

Simultaneously, the FDA is cracking down on telehealth companies prescribing compounded versions of glucagon-like peptide-1 (GLP-1) medications, commonly used for weight loss. The agency issued warnings regarding the safety and legality of these practices, raising concerns about patient safety and the integrity of the drug supply. This action highlights the FDA’s increasing focus on the rapidly evolving telehealth landscape and the potential risks associated with compounded medications.

Broader Implications for the Biotech Industry

These developments occur alongside other significant events in the biotech sector, including a major patent settlement for Moderna and advancements in myeloma treatment approvals. The FDA’s recent actions suggest a dynamic and, at times, unpredictable regulatory environment, potentially impacting innovation and investment within the industry. Experts have suggested that the FDA’s rejection of Moderna could stifle broader vaccine industry innovation.